Lexaria Bioscience (LEXX) Minority Interest (2014 - 2026)
Lexaria Bioscience (LEXX) posted Minority Interest of -$393970.0 for Q2 2026, little changed sequentially from -$392191.0 in Q1 2026, and down 2.18% YoY from -$402763.8 in Q2 2025.
Lexaria Bioscience (LEXX) Minority Interest (2014 - 2026) Analysis & Trends
Lexaria Bioscience has reported Minority Interest for 12 years, with the latest figure at -$393970.0 in Q2 2026.
- Quarterly Minority Interest fell 2.18% year-over-year to -$393970.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$393970.0 (down 2.18% YoY) and the FY2025 annual result came in at -$386942.0, down 2.54% from the prior year.
- Minority Interest was little changed at -$393970.0 in Q2 2026 per LEXX's latest filing, from -$392191.0 in the prior quarter.
- Over five years, Minority Interest peaked at -$235307.0 in Q1 2022 and troughed at -$393970.0 in Q2 2026.
- A 5-year average of -$356717.3 and a median of -$374258.5 in 2024 frame the typical range for Minority Interest.
- The sharpest annual moves came in 2022 and 2026: Minority Interest tumbled 249.26% in 2022, then retreated 2.12% in 2026.
- Over 5 years, Minority Interest stood at -$329776.0 in 2022, then fell by 12.12% to -$369755.0 in 2023, then decreased by 2.85% to -$380278.0 in 2024, then slipped by 2.41% to -$389438.0 in 2025, then declined by 1.16% to -$393970.0 in 2026.
- According to Business Quant data, Minority Interest over the past three periods registered -$393970.0, -$392191.0, and -$389438.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -393,970.00 |
| Feb 28, 2026 | -392,191.00 |
| Nov 30, 2025 | -389,438.00 |
| Aug 31, 2025 | -386,942.00 |
| May 31, 2025 | -385,552.00 |
| Feb 28, 2025 | -384,038.00 |
| Nov 30, 2024 | -380,278.00 |
| Aug 31, 2024 | -377,349.00 |
| May 31, 2024 | -375,568.00 |
| Feb 29, 2024 | -372,949.00 |
| Nov 30, 2023 | -369,755.00 |
| Aug 31, 2023 | -364,040.00 |
| May 31, 2023 | -354,344.00 |
| Feb 28, 2023 | -342,283.00 |
| Nov 30, 2022 | -329,776.00 |
| Aug 31, 2022 | -316,414.00 |
| May 31, 2022 | -270,718.00 |
| Feb 28, 2022 | -235,307.00 |
| Nov 30, 2021 | -212,410.00 |
| Aug 31, 2021 | -202,085.00 |